Bio-Path Holdings Inc. (BPTH) Plunges 12.96% on January 14

Bio-Path Holdings Inc. (BPTH) Plunges 12.96% on January 14

Bio-Path Holdings Inc. (BPTH) had a rough trading day for Monday January 14 as shares tumbled 12.96%, or a loss of $-0.0298 per share, to close at $0.20. After opening the day at $0.22, shares of Bio-Path Holdings Inc. traded as high as $0.24 and as low as $0.20. Volume was 134,821 shares over 278 trades, against an average daily volume of n/a shares and a total float of 13.6 million.

As a result of the decline, Bio-Path Holdings Inc. now has a market cap of $2.72 million. In the last year, shares of Bio-Path Holdings Inc. have traded between a range of $3.09 and $0.15, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

Bio-Path Holdings Inc is a US-based clinical and preclinical stage company. It focuses on oncology antisense drug development utilizing a novel technology. The company’s drug delivery and antisense technology referred as DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by enzymes when circulating in vivo, incorporated inside of a neutrally charged lipid bilayer. The lead drug candidate of the company is prexigebersen which is a nonproprietary drug for acute myeloid leukemia as well as solid tumors, including breast cancer and ovarian cancer. Its other drug candidate is Liposomal Bcl2 which targets the protein Bcl2, which is responsible for driving cell proliferation of all cancers.

Bio-Path Holdings Inc. is based out of Bellaire, TX and has some 9 employees. Its CEO is Peter H. Nielsen.

error: Content is protected !!